NCT02455557 2026-02-25
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT01903330 2025-03-05
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
Phase 2 Active not recruiting
NCT04013672 2024-08-28
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03927222 2024-04-08
I-ATTAC
Duke University
Phase 2 Terminated
NCT00643097 2017-02-01
ACTIVATe
Duke University
Phase 2 Completed
NCT00003185 2013-12-04
Biological Therapy in Treating Patients With Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00014573 2013-04-08
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00004024 2013-04-05
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00008008 2013-02-04
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
Phase 2 Completed